Zogenix Revenue and Competitors

Claim your profile



Total Funding



Estimated Revenue & Valuation

  • Zogenix's estimated annual revenue is currently $24.1M per year.(i)
  • Zogenix received $288.9M in venture funding in October 2017.
  • Zogenix's estimated revenue per employee is $211,579
  • Zogenix's total funding is $1.5B.

Employee Data

  • Zogenix has 114 Employees.(i)
  • Zogenix grew their employee count by -9% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Zogenix is committed to developing and commercializing therapies for central nervous system disorders that address specific clinical needs for people living with rare diseases and other CNS disorders who need innovative treatment alternatives to improve their daily functioning. We seek best-in-class leaders with scientific, medical and commercial expertise in the therapeutic areas in which we participate. By sharing a collective passion for making a difference in the lives of patients we serve, our unique company culture thrives through the principles of ethical decision making, open communication and collaboration.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Zogenix News

2022-04-13 - Zogenix (NASDAQ:ZGNX) Now Covered by StockNews.com

Northland Securities downgraded shares of Zogenix from an “outperform” rating to a “market perform” rating in a report on Monday, February 28th.

2022-04-06 - Zogenix (NASDAQ:ZGNX) Coverage Initiated by Analysts at ...

JMP Securities downgraded Zogenix from an outperform rating to a market perform rating in a research note on Wednesday, January 19th. Zacks...

2022-04-06 - Zogenix, Inc. (NASDAQ:ZGNX) Given Average ...

Zogenix, Inc. (NASDAQ:ZGNX) Given Average Recommendation of “Hold” by Brokerages. Posted by admin on Apr 13th, 2022.

2021-08-09 - Zogenix Dravet Syndrome Photo Diary Contest Raises $50,000 for Dravet Syndrome and Epilepsy Foundations

EMERYVILLE, Calif., Aug. 9, 2021 /PRNewswire/ -- Zogenix, a global biopharmaceutical company developing rare disease therapies, today announced it will donate $50,000 to be equally divided between the Dravet Syndrome Foundation and Epilepsy Foundation, in support of the work they do for patien ...

2019-09-12 - Zogenix Completes Acquisition of Modis Therapeutics, Inc.

EMERYVILLE, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Zogenix Funding

DateAmountRoundLead InvestorsReference
2006-08-29$60.0MAClarus Ventures, Domain Associates LLCArticle
2006-09-28$60.0MUndisclosedClarus Ventures, Domain AssociatesArticle
2008-01-10$18.0MUndisclosedAbingworth Management LtdArticle
2008-07-29$18.0MUndisclosedOxford Finance Corporation, CIT Healthcare LLCArticle
2009-09-24$51.0MUndisclosedClarus Ventures, Domain AssociatesArticle
2009-12-08$35.0MUndisclosedChicago Growth Partners, Clarus VenturesArticle
2010-07-14$50.0MUndisclosedOxford Finance CorporationArticle
2015-07-31$98.3MUndisclosedLeerink Partners LLCArticle
2017-10-04$288.9MUndisclosedLeerink Partners LLCArticle